Oncolytics to present reovirus research results

Oncolytics Biotech will present multiple research reports on oncolytic reovirus studies at the American Society of Clinical Oncology meeting. "Reolysin," the company's proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumor cells bearing an activated Ras pathway. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders. Oncolytics release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.